Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling

References

• Iqbal J, Shen Y, Huang X, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125(7):1137–1145.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14(6):460–467.e2.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international scholar-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209–216.
   PubMed Web of Science ®Google Scholar
• Cherng HJ, Alig S, Oki Y, et al. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023;7(7):1137–1145.
   Google Scholar
• Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–e308.
   PubMed Web of Science ®Google Scholar
• Alrefaei AF, Abu-Elmagd M. LRP6 receptor plays essential functions in development and human diseases. Genes. 2022;13(1):120.
   PubMed Web of Science ®Google Scholar
• Tamai K, Zeng X, Liu C, et al. A mechanism for WNT coreceptor activation. Mol Cell. 2004;13(1):149–156.
   PubMed Web of Science ®Google Scholar
• Roslan Z, Muhamad M, Selvaratnam L, et al. The roles of low-density lipoprotein receptor-related proteins 5, 6, and 8 in cancer: a review. J Oncol. 2019;2019:4536302.
   PubMed Web of Science ®Google Scholar
• Yao Q, An Y, Hou W, et al. LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics. Oncotarget. 2017;8(65):109632–109645.
   PubMedGoogle Scholar
• Mao X, Tey SK, Ko FCF, et al. C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett. 2019;444:60–69.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shu C, Maimaiti Y, et al. LRP6 as a biomarker of poor prognosis of breast cancer. Gland Surg. 2021;10(8):2414–2427.
   PubMed Web of Science ®Google Scholar
• Raisch J, Côté-Biron A, Rivard N. A role for the WNT co-receptor LRP6 in pathogenesis and therapy of epithelial cancers. Cancers. 2019;11(8):1162.
   PubMed Web of Science ®Google Scholar
• Zhou S, Wang F, Wong ET, et al. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem. 2013;20(33):4095–4101.
   PubMed Web of Science ®Google Scholar
• Lu W, Li Y. Salinomycin suppresses LRP6 expression and inhibits both wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014;115(10):1799–1807.
   PubMed Web of Science ®Google Scholar
• Lu D, Choi MY, Yu J, et al. Salinomycin inhibits wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011;108(32):13253–13257.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang XQ, Wang JC, et al. A comparison study of the cytotoxicity of salinomycin and salinomycin sodium toward human breast cancer stem cells as well as breast cancer cells. J Chin Pharm Sci. 2011;20(4): 368-375.
   Google Scholar
• Zhou J, Sun J, Chen H, et al. Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles. Int J Oncol. 2018;53(3):1289–1300.
   PubMed Web of Science ®Google Scholar
• Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19(9):14304–14315.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: r -CHOP failure–what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378.
   PubMed Web of Science ®Google Scholar
• Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3(1):66–70.
   PubMedGoogle Scholar
• Zhou T, Zhan J, Fang W, et al. Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC). BMC Cancer. 2017;17(1):269.
   PubMedGoogle Scholar
• Cheng Z, Biechele T, Wei Z, et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol. 2011;18(11):1204–1210.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, He X. Frizzled and LRP5/6 receptors for WNT/β-catenin signaling. Cold Spring Harb Perspect Biol. 2012;4(12): a007880.
   Google Scholar
• Go GW. Low-density lipoprotein receptor-related protein 6 (LRP6) is a novel nutritional therapeutic target for hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis. Nutrients. 2015;7(6):4453–4464.
   PubMed Web of Science ®Google Scholar
• Haseeb M, Pirzada RH, Ain QU, et al. WNT signaling in the regulation of immune cell and cancer therapeutics. Cells. 2019;8(11):1380.
   PubMed Web of Science ®Google Scholar
• Fenderico N, van Scherpenzeel RC, Goldflam M, et al. Anti-LRP5/6 VHHs promote differentiation of wnt-hypersensitive intestinal stem cells. Nat Commun. 2019;10(1):365.
   PubMedGoogle Scholar
• Lin C, Lu W, Zhai L, et al. Mesd is a general inhibitor of different wnt ligands in wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett. 2011;585(19):3120–3125.
   PubMed Web of Science ®Google Scholar
• Tefas LR, Barbălată C, Tefas C, et al. Salinomycin-based drug delivery systems: overcoming the hurdles in cancer therapy. Pharmaceutics. 2021;13(8):1120.
   PubMed Web of Science ®Google Scholar
• Qi D, Liu Y, Li J, et al. Salinomycin as a potent anticancer stem cell agent: state of the art and future directions. Med Res Rev. 2022;42(3):1037–1063.
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–659.
   PubMed Web of Science ®Google Scholar
• Huang J, Nguyen-McCarty M, Hexner EO, et al. Maintenance of hematopoietic stem cells through regulation of WNT and mTOR pathways. Nat Med. 2012;18(12):1778–1785.
   PubMed Web of Science ®Google Scholar
• Tahir SA, Yang G, Goltsov A, et al. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 2013;73(6):1900–1911.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu Y, Sun X, et al. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. BMC Cancer. 2022;22(1):190.
   PubMed Web of Science ®Google Scholar
• Ezell SA, Wang S, Bihani T, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7(8):9163–9174.
   PubMedGoogle Scholar
• Eyre TA, Collins GP, Goldstone AH, et al. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. Br J Haematol. 2014;166(3):336–351.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Boyer JA, Burnett GL, et al. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nat Chem Biol. 2021;17(10):1065–1074.
   PubMed Web of Science ®Google Scholar